CO5700763A2 - Derivados de 1-bencil-5-piperazin-1-il-3,4-dihidro-1h-quinazolin-2-ona y el respexctivo 1h-benzo (1,2,6)tiadiazin-2,2-dioxido y derivados de 1,4-dihidro-benzo (d) (1,3) oxazin-2-ona como moduladores del receptor 5-hidroxitriptamina (5-ht) para el tra - Google Patents

Derivados de 1-bencil-5-piperazin-1-il-3,4-dihidro-1h-quinazolin-2-ona y el respexctivo 1h-benzo (1,2,6)tiadiazin-2,2-dioxido y derivados de 1,4-dihidro-benzo (d) (1,3) oxazin-2-ona como moduladores del receptor 5-hidroxitriptamina (5-ht) para el tra

Info

Publication number
CO5700763A2
CO5700763A2 CO06068258A CO06068258A CO5700763A2 CO 5700763 A2 CO5700763 A2 CO 5700763A2 CO 06068258 A CO06068258 A CO 06068258A CO 06068258 A CO06068258 A CO 06068258A CO 5700763 A2 CO5700763 A2 CO 5700763A2
Authority
CO
Colombia
Prior art keywords
ona
benzo
derivatives
alkyl
links
Prior art date
Application number
CO06068258A
Other languages
English (en)
Inventor
Meng Sui
Shu Hai Zhao
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO5700763A2 publication Critical patent/CO5700763A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

1.- Un compuesto de la formula (I): o una sal farmacéuticamente aceptable del mismo, en donde:Y es C o S;m es 1 cuando Y es C y m es 2 cuando Y es S;n es 1 o 2;p es de 0 a 3;q es de 1 a 3;Z es -(CRaRb),- o -SO2-, en donde r es de 0 a 2 y cada uno de Ra y Rb es independientemente hidrógeno o alquilo;X es CH o N;cada R1 es independientemente: halo; alquilo, haloalquilo; heteroarilo; alcoxi; ciano; -S(O)s-Rc; -C(=O)-NRcRd; -N(Rc)-C(=O)-Rd; o -C(=O)Rc; en donde s es de 0 a 2 y cada uno de Rc y Rd es independientemente hidrógeno o alquilo;R2 es arilo opcionalmente sustituido o heteroarilo opcionalmente sustituido con la condición que R2 no es fenilo sustituido por un grupo formamidinilo;A es -NR3- o -O- en donde R3 es: hidrógeno, alquilo, acilo, amidoalquilo, hidroxialquilo o alcoxialquilo;cada uno de R4 y R5 es independientemente hidrógeno o alquilo, o uno de R4 y R5 junto con sus carbonos compartidos pueden formar un anillo de 3 a 6 eslabones que incluye opcionalmente un heteroátomo de nitrógeno u oxígeno; ycada uno de R6, R7, R8, R9 y R10 es independientemente hidrógeno o alquilo, o uno de R6 y R7 junto con R10 y los átomos a los cuales están unidos, pueden formar un anillo de 3 a 7 eslabones, o uno de R6 y R7 junto con los átomos a los cuales están unidos pueden formar un anillo de 3 a 7 eslabones, o uno de R6 y R7 junto con uno de R8 y R9 y los átomos a los que están unidos pueden formar un anillo de 3 a 7 eslabones.
CO06068258A 2004-01-16 2006-07-13 Derivados de 1-bencil-5-piperazin-1-il-3,4-dihidro-1h-quinazolin-2-ona y el respexctivo 1h-benzo (1,2,6)tiadiazin-2,2-dioxido y derivados de 1,4-dihidro-benzo (d) (1,3) oxazin-2-ona como moduladores del receptor 5-hidroxitriptamina (5-ht) para el tra CO5700763A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53708004P 2004-01-16 2004-01-16

Publications (1)

Publication Number Publication Date
CO5700763A2 true CO5700763A2 (es) 2006-11-30

Family

ID=34794441

Family Applications (1)

Application Number Title Priority Date Filing Date
CO06068258A CO5700763A2 (es) 2004-01-16 2006-07-13 Derivados de 1-bencil-5-piperazin-1-il-3,4-dihidro-1h-quinazolin-2-ona y el respexctivo 1h-benzo (1,2,6)tiadiazin-2,2-dioxido y derivados de 1,4-dihidro-benzo (d) (1,3) oxazin-2-ona como moduladores del receptor 5-hidroxitriptamina (5-ht) para el tra

Country Status (19)

Country Link
US (2) US7196087B2 (es)
EP (1) EP1708713B1 (es)
JP (1) JP4533391B2 (es)
KR (1) KR100843053B1 (es)
CN (1) CN1909909B (es)
AR (1) AR047958A1 (es)
AT (1) ATE388712T1 (es)
AU (1) AU2005205016B2 (es)
BR (1) BRPI0506909A (es)
CA (1) CA2552681A1 (es)
CO (1) CO5700763A2 (es)
DE (1) DE602005005298T2 (es)
ES (1) ES2302174T3 (es)
IL (1) IL176631A0 (es)
NO (1) NO20062791L (es)
RU (1) RU2006129464A (es)
TW (1) TW200530222A (es)
WO (1) WO2005067933A1 (es)
ZA (1) ZA200605434B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2348467T3 (es) * 2004-09-30 2010-12-07 F. Hoffmann-La Roche Ag Derivados y usos de la benzoxazina y la quinoxalina.
US7713954B2 (en) * 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
EP1836183A2 (en) * 2004-12-13 2007-09-26 Galileo Pharmaceuticals, Inc. Spiro derivatives as lipoxygenase inhibitors
AU2006268713A1 (en) * 2005-07-13 2007-01-18 F. Hoffmann-La Roche Ag Benzimidazole derivatives as 5-HT6,5-HT24
KR100817538B1 (ko) * 2006-07-05 2008-03-27 한국화학연구원 신규 치환된―１ｈ―퀴나졸린―２,４―디온 유도체, 이의제조방법 및 이를 함유하는 약학적 조성물
JP5256202B2 (ja) * 2006-09-11 2013-08-07 エム・エス・ディー・オス・ベー・フェー キナゾリノンおよびイソキノリノンアセトアミド誘導体
WO2008073958A2 (en) 2006-12-12 2008-06-19 Wyeth Substituted benzothiadiazinedioxide derivatives and methods of their use
BRPI0822462A2 (pt) * 2008-06-20 2015-10-13 Rottapharm Spa derivados de 6-1h-imidazo-quinazolina e de quinolinas, novos inibidores de mao e ligantes a receptor de imidazolina.
KR20110038180A (ko) 2008-09-08 2011-04-13 에프. 호프만-라 로슈 아게 5-치환된 벤즈옥사진
MX2012013527A (es) 2010-05-21 2013-04-08 Shanghai Inst Pharm Industry Quinazolinas policíclicas, preparación de las mismas, y uso de las mismas.
WO2018093818A1 (en) * 2016-11-15 2018-05-24 Temple University-Of The Commonwealth System Of Higher Education Novel modulators of the 5-hydroxytryptamine receptor 7 and their method of use
JP2023501000A (ja) * 2019-10-21 2023-01-17 アライリオン インコーポレイテッド 睡眠障害の治療のためのＨ１および５－ＨＴ２Ａ受容体調節物質としての３－（４－（１１Ｈ－ジベンゾ［ｂ，ｅ］［１，４］アゼピン－６－イル）ピペラジン－１－イル）－プロパン酸誘導体および３－（４－（ジベンゾ［ｂ，ｆ］［１，４］オキサゼピン／チアゼピン／ジアゼピン－１１－イル）ピペラジン－１－イル）－プロパン酸誘導体

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3642791A (en) * 1969-08-13 1972-02-15 Sandoz Ag Morpholino-1-substituted-2(1h)-quinazolinones
JPS5271483A (en) * 1975-12-11 1977-06-14 Sumitomo Chem Co Ltd Synthesis of 2(1h)-quinazolinone derivatives
CN1015459B (zh) * 1985-06-06 1992-02-12 田边制药株式会社 喹唑啉酮化合物的制备方法
GR1000821B (el) * 1988-11-22 1993-01-25 Tanabe Seiyaku Co Μεθοδος παραγωγης παραγωγων κιναζολινονης.
WO1998018781A2 (en) 1996-10-28 1998-05-07 Versicor, Inc. Fused 2,4-pyrimidinedione combinatorial libraries, their preparation and the use of fused 2,4-pyrimidinediones derivatives as antimicrobial agents
WO1998042688A1 (fr) 1997-03-26 1998-10-01 Sumitomo Pharmaceuticals Co., Ltd. Derives de 4-arylmethylene-1,4-dihydro-2h-azine
DK1028950T3 (da) 1997-10-28 2003-09-01 Warner Lambert Co 7-substituerede quinazolin-2,4-dioner nyttige som antibakterielle midler
AU2074699A (en) * 1998-01-26 1999-08-09 Yamanouchi Pharmaceutical Co., Ltd. Novel benzene-fused heterocyclic derivatives or salts thereof
AU1028601A (en) * 1999-11-05 2001-05-14 Smithkline Beecham Plc Isoquinoline and quinazoline derivatives having a combined 5ht1a, 5ht1b and 5ht1d receptor activity
EP1248624A4 (en) 1999-11-23 2003-01-22 Smithkline Beecham Corp 3,4-DIHYDRO- (1H) -CHIRAZOLINE-2-ONES AND THE USE THEREOF AS CSBP / P38 KINASE INHIBITORS
AU2525701A (en) 1999-12-14 2001-06-25 Sanofi-Synthelabo Derivatives of quinazolinedione phthalimide, preparations thereof and their therapeutic uses
JP2004521892A (ja) * 2000-12-20 2004-07-22 メルク　エンド　カムパニー　インコーポレーテッド （ハロ−ベンゾカルボニル）複素環縮合フェニル系ｐ３８キナーゼ阻害剤
US6998408B2 (en) * 2001-03-23 2006-02-14 Bristol-Myers Squibb Pharma Company 6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors
BR0210411A (pt) * 2001-06-15 2004-08-17 Hoffmann La Roche Derivados 4-piperazinilindol com afinidade para o receptor 5-ht6
GB0203804D0 (en) * 2002-02-18 2002-04-03 Glaxo Group Ltd Compounds
UA76877C2 (uk) * 2002-05-13 2006-09-15 Ф.Хоффманн-Ля Рош Аг Похідні бензоксазину як 5-нт6 модулятори і їх застосування

Also Published As

Publication number Publication date
DE602005005298D1 (de) 2008-04-24
DE602005005298T2 (de) 2009-03-12
AU2005205016A1 (en) 2005-07-28
JP2007517826A (ja) 2007-07-05
WO2005067933A1 (en) 2005-07-28
JP4533391B2 (ja) 2010-09-01
AR047958A1 (es) 2006-03-15
BRPI0506909A (pt) 2007-05-29
CA2552681A1 (en) 2005-07-28
US20070149510A1 (en) 2007-06-28
US20050165001A1 (en) 2005-07-28
TW200530222A (en) 2005-09-16
ATE388712T1 (de) 2008-03-15
RU2006129464A (ru) 2008-02-27
AU2005205016B2 (en) 2010-07-15
IL176631A0 (en) 2006-10-31
EP1708713A1 (en) 2006-10-11
US7365063B2 (en) 2008-04-29
ES2302174T3 (es) 2008-07-01
KR100843053B1 (ko) 2008-07-01
CN1909909A (zh) 2007-02-07
CN1909909B (zh) 2010-12-15
NO20062791L (no) 2006-08-01
US7196087B2 (en) 2007-03-27
EP1708713B1 (en) 2008-03-12
KR20060126720A (ko) 2006-12-08
ZA200605434B (en) 2008-02-27

Similar Documents

Publication Publication Date Title
CO5700763A2 (es) Derivados de 1-bencil-5-piperazin-1-il-3,4-dihidro-1h-quinazolin-2-ona y el respexctivo 1h-benzo (1,2,6)tiadiazin-2,2-dioxido y derivados de 1,4-dihidro-benzo (d) (1,3) oxazin-2-ona como moduladores del receptor 5-hidroxitriptamina (5-ht) para el tra
ES2515095T3 (es) Derivados de adamantil acetamida como inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo 1
CO6210770A2 (es) Compuestos 2-aril-5-heterociclil-ciclohexan-1, 3 diona y su uso como herbicidas
AR076170A1 (es) Derivados heterociclicos imidazolicos y/o oxazolicos utiles como agentes antivirales para hepatitis c y composiciones farmaceuticas que los comprenden.
AR054024A1 (es) Derivados de piridina -3- carboxamida como agonistas inversos de cb1
UY31014A1 (es) Derivados de ftalazinona
CO5680412A2 (es) Agonistas del receptor adrenergico etilamino beta 2 sustituido con amino
CO6220907A2 (es) 4-fenil-piran-3,5-dionas, 4-fenil-tiopiran-3,5-dionas y ciclohexantrionas como nuevos herbicidas
PE20110397A1 (es) Compuestos que modulan selectivamente el receptor cb2
AR082886A1 (es) Compuestos y composiciones farmaceuticas que los contienen
AR048669A1 (es) Derivados biciclicos de bisamida
AR054814A1 (es) Derivados de piridazina
TNSN07255A1 (en) Cyclohexylamides as dopamine d3, d2 and 5ht 1a antagonists
PE20130375A1 (es) Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos
PE20141041A1 (es) Compuestos, metodos y formulaciones parasiticidas
AR055592A1 (es) Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace)
ME01421B (me) 5-supstituisani derivati kinazolinona kao protivtumorska sredstva
AR051995A1 (es) Derivados de tieno-piridina como intensificadores alostericos de gaba -b
EA201101089A1 (ru) Производные оксадиазола в качестве агонистов рецептора s1p1
AR040546A1 (es) Derivados de la 1-h- pirrolidin -2,4- diona espirociclicos, cis- alcoxisubstituidos
AR056979A1 (es) Derivados de dihidrobenzofuranos y usos de los mismos
AR050281A1 (es) Derivados de indol, indazol e indazolina. procesos de obtencion y composiciones farmaceuticas
CO6220935A2 (es) Derivados de 1,2,4-triazol como moduladores de mglur5
RS52562B (en) (3-ARIL-PIPERAZINE-1-IL) DERIVATI 6,7-DIALCOKSIQUINZOLINE, 6,7-DIALCOKSIFTALAZINE I
AR059328A1 (es) Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp

Legal Events

Date Code Title Description
FC Application refused